Shares of Oxford BioDynamics Plc (LON:OBD – Get Free Report) were up 20% during mid-day trading on Wednesday. The stock traded as high as GBX 0.12 and last traded at GBX 0.12. Approximately 150,116,031 shares traded hands during trading, an increase of 534% from the average session volume of 23,669,771 shares. The stock had previously closed at GBX 0.10.
Oxford BioDynamics Price Performance
The company has a current ratio of 2.01, a quick ratio of 2.80 and a debt-to-equity ratio of 131.61. The company has a market cap of £15.32 million, a P/E ratio of -0.57 and a beta of 0.42. The business’s fifty day moving average is GBX 0.12 and its 200 day moving average is GBX 0.15.
Oxford BioDynamics Company Profile
Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.
Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.
In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.
Recommended Stories
- Five stocks we like better than Oxford BioDynamics
- 3 Stocks to Watch as Wall Street Wealth Fuels Consumer Spending
- Expecting a Market Correction? This Mega-Cap ETF Deserves a Spot on Your Watchlist
- ASML Can’t Keep Up With AI Demand—Why That’s a Good Thing
- Enovix’s 100,000-Battery Drone Order Sets Up a Test of Its Production Plans
Receive News & Ratings for Oxford BioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.
